Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany

European Journal of Cancer Prevention

Volumn 21, Issue 6, 2012, Pages 552-559

  Braisch, Ulrike ^a   Meyer, Martin ^a   Radespiel Tröger, Martin ^a  

^a Population Based Cancer Registry Bavaria   (Germany)

Author keywords

Cancer registry; Population based; Prostate cancer; Risk; Subsequent primary cancer

Indexed keywords

ARTICLE; BLADDER CANCER; BRAIN CANCER; CANCER REGISTRY; CANCER RISK; FOLLOW UP; GERMANY; HIGH RISK PATIENT; HUMAN; KIDNEY CANCER; KIDNEY PELVIS CANCER; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOMA; NERVOUS SYSTEM TUMOR; PANCREAS CANCER; POPULATION RESEARCH; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SMALL INTESTINE CANCER; SUBSEQUENT PRIMARY CANCER; THYROID CANCER; URETER CANCER;

GERMANY; HUMANS; INCIDENCE; MALE; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84866977640     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328351c748     Document Type: Article

References (46)

1. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA (2005). Increased risk of rectal cancer after prostate radiation: a populationbased study. Gastroenterology 128:819-824.
2. Brenner DJ (2006). Induced second cancers after prostate-cancer radiotherapy: no cause for concern? Int J Radiat Oncol Biol Phys 65:637-639.
3. Brenner DJ, Curtis RE, Hall EJ, Ron E (2000). Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:398-406.
4. Cassetti T, Stracci F, Minelli L, Scheibel M, Sapia IE, La Rosa F (2008). Metachronous malignancies in men with previous prostate cancer in Umbria, Italy, 1994-2003. Tumori 94:7-10.
5. Cluze C, Delafosse P, Seigneurin A, Colonna M (2009). Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 18:343-348.
6. Coughlin SS, Neaton JD, Sengupta A (1996). Cigarette smoking as a predictor of death from prostate cancer in 348 874 men screened for the multiple risk factor intervention trial. Am J Epidemiol 143:1002-1006.
7. Croswell JM, Kramer BS, Crawford ED (2011). Screening for prostate cancer with PSA testing: current status and future directions. Oncology 25: 452-460, 463.
8. Curtis RE, Ries LAG (2006). Methods. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000, NIH Publ. No. 05-5302. Bethesda: National Cancer Institute; pp. 9-14.
9. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, et al. (1998). Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasie and prostate cancer. J Natl Cancer Inst 90:519-523.
10. Dos Santos Silva I (1999). Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer.
11. Eisinger B (2008). Guideline for standardised coding of urothelial tumours of the urinary bladder. In: Hentschel S, Katalinic A, editors. Manual of epidemiological cancer registration. Mü nchen: W. Zuckschwerdt Verlag; pp. 87-90.
12. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94:981-990.
13. Fellegi IP, Sunter AB (1969). A theory for record linkage. JASA 64:1183-1210.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; Available at http://globocan.iarc.fr. [Accessed 13 October 2011]
15. Garwood F (1936). Fiducial limits for the Poisson distribution. Biometrika 28:437-442.
16. Goldstraw MA, Payne H, Kirby RS (2006). What are the risks of second cancer formation after radiotherapy to the prostate? BJU Int 98:489-491.
17. Haberland J, Bertz J, Görsch B, Schön D (2001). Estimation of cancer incidence in Germany using log-linear models. Health Care 63:556-560.
18. Hayes RB, Pottern LM, Swanson GM, Liff JM, Schoenberg JB, Greenberg RS, et al. (1994). Tobacco use and prostate cancer in Blacks and Whites in the United States. Cancer Causes Control 5:221-226.
19. Heard A, Roder D, Luke C (2005). Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia). Cancer Causes Control 16:475-481.
20. Hellawell GO, Dearden JC (2007).What are the risks of second cancer formation after radiotherapy to the prostate? BJU Int 99:698.
21. Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G,Wacholder S, et al. (1990). Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 50:6836-6840.
22. Hsing AW, McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. (1991). Tobacco use and prostate cancer: a 26-year follow-up of US veterans. Am J Epidemiol 133:437-441.
23. Kendal WS, Eapen L, MacRae R, Malone S, Nicholas G (2006). Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys 65: 661-668.
24. Levi F, Randimbison L, Te VC, Erler G, La Vecchia C (1999). Second primary tumors after prostate carcinoma. Cancer 86:1567-1570.
25. McCredie M, Macfarlane GJ, Stewart J, Coates M (1996). Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972-1991. Cancer Causes Control 7:337-344.
26. McMaster ML, Feuer EJ, Tucker MA (2006). New malignancies following cancer of the male genital tract. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000, NIH Publ. No. 05-5302. Bethesda: National Cancer Institute; pp. 257-284.
27. Meyer M, Radespiel-Tröger M, Vogel C (2005). Probabilistic record linkage of anonymous cancer registry records. In: Baier D, Wernecke KD, editors. Innovations in classification, data science, and information systems: proceedings of the 27th annual conference of the Gesellschaft für Klassifikation e.V., Brandenburg University of Technology, Cottbus, March 12-14, 2003. Berlin: Springer; pp. 599-604.
28. Neugut AI, Ahsan H, Robinson E, Ennis RD (1997). Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79:1600-1604.
29. Patel AR, Klein EA (2009). Risk factors for prostate cancer. Nat Clin Prac Urol 6:87-95.
30. Pawlish KS, Schottenfeld D, Severson R, Montie JE (1997). Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate 33:75-86.
31. Pickles T, Phillips N (2002). The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 65:145-151.
32. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. (2000). Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592.
33. Quinn M, Babb P (2002a). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90:162-173.
34. Quinn M, Babb P (2002b). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 90:174-184.
35. R Development Core Team (2010). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available at http://www.R-project.org. [Accessed 13 October 2011]
36. Robert Koch Institute (2010). Distribution of cancer diseases in Germany. Time trends of prevalences between 1990 and 2010. Berlin: Robert Koch Institute; pp. 98-102.
37. Robert Koch Institute and Association of Population-Based Cancer Registries in Germany (2010). Cancer in Germany 2005/2006. Incidence and Trends. 7th ed. Berlin: Robert Koch Institute.
38. Sahai H, Khurshid A (1993). Confidence intervals for the mean of a Poisson distribution: a review. Biom J 35:857-867.
39. Schoenberg BS, Myers MH (1977). Statistical methods for studying multiple primary malignant neoplasms. Cancer 40:1892-1898.
40. Signorello LB, Adami HO (2002). Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. New York: Oxford University Press; pp. 400-428.
41. Sonn GA, Aronson W, Litwin MS (2005). Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8:304-310.
42. Thellenberg C, Malmer B, Tavelin B, Grönberg H (2003). Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 169:1345-1348.
43. Travis LB, Hodgson D, Allan JM, Van Leeuwen FE (2008). Second cancers. In: De Vita VTJr, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins; pp. 2718-2719.
44. Van der Gulden JWJ, Verbeek ALM, Kolk JJ (1994). Smoking and drinking habits in relation to prostate cancer. BJU Int 73:382-389.
45. Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D (2009). Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol Biomarkers Prev 18:2427-2435.
46. WHO (1992). International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10). Geneva: World Health Organization; 1992.